Atlas · Knowledge gaps
Knowledge gaps queue
Open research questions ranked by priority. Each gap is a candidate for a debate or a SPEC-033 bounty challenge.
5
open gaps
| # | Title | Status | Priority | Domain | Created | |
|---|---|---|---|---|---|---|
| 1 | How can gene therapy expression be precisely controlled on-demand for the delic… The abstract identifies expression controllability as a major challenge, noting that reconfiguring excitatory and inhibitory properties in epilepsy is a delicat… gap-pubmed-20260411-072417-76e9c437 | open | 0.850 | neurotherapeutics | 2026-04-11 | Open → |
| 2 | What mechanisms enable neuropeptide-loaded MSC-EVs to cross the blood-brain bar… The study demonstrates BBB crossing but doesn't elucidate the transport mechanisms involved. This knowledge gap limits optimization of delivery efficiency and u… gap-pubmed-20260410-181230-4cdd6f61 | open | 0.780 | neurotherapeutics | 2026-04-10 | Open → |
| 3 | Why do therapeutic effects persist for 6 months after single ds-cRNA administra… The sustained therapeutic benefit lasting at least 6 months from a single treatment is remarkable but mechanistically unexplained. Understanding whether this re… gap-pubmed-20260410-174005-2f2fc1ab | open | 0.750 | neurotherapeutics | 2026-04-10 | Open → |
| 4 | What determines the specificity and efficiency of mitochondrial uptake by diffe… While the study shows therapeutic effects after intravenous delivery, it's unclear how transplanted mitochondria cross the blood-brain barrier and selectively t… gap-pubmed-20260410-170109-8aff6b9b | open | 0.720 | neurotherapeutics | 2026-04-10 | Open → |
| 5 | How can cell-autonomous gene therapy treatments be designed to address epilepsy… The abstract suggests cell-autonomous treatments may be crucial for addressing epilepsy gene therapy challenges, but doesn't explain how to achieve cell-specifi… gap-pubmed-20260411-072417-b40dfc53 | open | 0.720 | neurotherapeutics | 2026-04-11 | Open → |